A US class action litigation, which since 2017 has been hanging over Novo Nordisk and its three former executives, Lars Rebien Sørensen, Jesper Brandgaard and Jakob Riis, now seems to have reached its conclusion, the company reports in a press release.
The company writes that an agreement to settle has been reached in the case concerning alleged violations of the US securities laws. The plaintiffs, shareholders of Novo Nordisk, claimed that the company and aforementioned executives were guilty of market manipulation back in 2015 and 2016, when company share price took a significant dip over a long period.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
GN purchase story is very speculative, says analyst
Competition rules could block a purchase of GN Store Nord and subsequent divestment of GN Hearing, says a Sydbank analyst on the speculative story that this might be underway.
Novo Nordisk invests additional millions of dollars in new manufacturing facilities
Novo Nordisk’s DKK 17bn (USD 2.4bn) investment into upgrading and building new facilities in Kalundborg last year has now been followed by a DKK 1bn (USD 143.8m) investment in the same location.
CHMP to remove 100 generic medicines from market
Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.
Germany orders 40,000 monkeypox vaccines from Bavarian Nordic
The German Minister for Health has revealed that the German state has ordered vaccines from Bavarian Nordic, as the country reports 5 cases of monkeypox.
New head of research at Astellas Gene Therapies: "Choosing the right indications is extra important"
Morten Søgaard is leaving Pfizer to join Astellas, where he will be in charge of 100 employees. Going from one of the world largest pharmaceutical firms to a considerably smaller one will be a challenge, he says.
Senior IT Network Engineer 
2 Sales Representatives and Product Specialists 
Biostatistician 
Client Talent Acquisition Specialist 
Analytical Senior Scientist 
System Sales Development Consultant - Investment Projects, Merck Millipore 
Innovation Project Manager, Display Unit 
Communications Consultant 
Production Director 
Nordic Medical Affairs Manager 
Clinical Trial Manager for development of in vitro diagnostics 
Clinical Trial Manager 
Senior Project Manager (GMP - Life Science) 
Account Manager 
KLIFO is looking for a Clinical Supply Manager for our Glostrup office